Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Santarus
August 12, 2016
Interview – Pharming’s last chance lies with solo strategy
November 07, 2014
Salix ruins its reputation with disastrous inventory admissions
July 11, 2014
Upcoming events: Alzheimer’s conference and US action on Ruconest
July 09, 2014
Ireland tax shelter beckons for Salix
July 02, 2014
Salix’s persistence pays off with IBS confirmation
April 07, 2014
Big pharma benefits from biotech carnage in Q1
November 08, 2013
Salix plays the long game with $2.6bn Santarus swoop
August 02, 2013
BioCryst eyes HAE market as Viropharma struggles to innovate
January 15, 2013
Uceris approval kicks off what could be a record year for Santarus
January 09, 2013
Sarepta joins the big league as best-performing 2012 share
December 24, 2012
Event – Santarus needs Uceris approval to boost flagging pipeline
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
July 07, 2020
What pandemic? Biotech floats break records
July 10, 2020
Venture investors: biotech's preppers?
June 17, 2020
Big pharma sports smallest late-stage pipeline for a decade
July 22, 2020
It’s official: “pipeline in a product” is a thing
April 22, 2020
Covid-19 antibody tests face a very specific problem
